
Meta-regression coefficients, by drug class, S4 - FDA approval/ not in market
======================================================================================
                      Outcome               Class    Slope    CI.lb    CI.ub   P-value
--------------------------------------------------------------------------------------
5               All-cause Mortality        GLP-1RA   -0.522   -5.867   4.824    0.848 
1            Cardiovascular Mortality      GLP-1RA   0.123    -5.078   5.325    0.963 
2                      MACE                GLP-1RA   -2.016   -7.377   3.344    0.461 
6              Myocardial Infarction       GLP-1RA   -0.293   -5.953   5.367    0.919 
7                     Stroke               GLP-1RA   -1.803   -6.751   3.145    0.475 
3        Hospitalization for Heart Failure GLP-1RA   0.402    -4.571   5.375    0.874 
4             Composite Renal Outcome      GLP-1RA   -3.567   -12.16   5.026    0.416 
12              All-cause Mortality         SGLT2i   0.328    -0.23    0.886    0.249 
8            Cardiovascular Mortality       SGLT2i   0.536    -0.052   1.124    0.074 
9                      MACE                 SGLT2i   1.151    -1.16    3.463    0.329 
13             Myocardial Infarction        SGLT2i   -0.15    -2.785   2.485    0.911 
14                    Stroke                SGLT2i   -0.081   -2.906   2.745    0.955 
10       Hospitalization for Heart Failure  SGLT2i   1.444    1.047    1.842      0   
11            Composite Renal Outcome       SGLT2i   0.297    -0.408   1.002    0.409 
--------------------------------------------------------------------------------------
Absolute risk difference and baseline cardiovascular mortality rate. Sensitivity      
